KR102389240B1 - 면역-종양 살상 요법 - Google Patents

면역-종양 살상 요법 Download PDF

Info

Publication number
KR102389240B1
KR102389240B1 KR1020167006785A KR20167006785A KR102389240B1 KR 102389240 B1 KR102389240 B1 KR 102389240B1 KR 1020167006785 A KR1020167006785 A KR 1020167006785A KR 20167006785 A KR20167006785 A KR 20167006785A KR 102389240 B1 KR102389240 B1 KR 102389240B1
Authority
KR
South Korea
Prior art keywords
virus
trif
tumor
vaccinia virus
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167006785A
Other languages
English (en)
Korean (ko)
Other versions
KR20160044529A (ko
Inventor
스테픈 호워드 토른
Original Assignee
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 filed Critical 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Publication of KR20160044529A publication Critical patent/KR20160044529A/ko
Application granted granted Critical
Publication of KR102389240B1 publication Critical patent/KR102389240B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020167006785A 2013-08-22 2014-08-22 면역-종양 살상 요법 Active KR102389240B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361868978P 2013-08-22 2013-08-22
US61/868,978 2013-08-22
PCT/US2014/052308 WO2015027163A1 (en) 2013-08-22 2014-08-22 Immuno-oncolytic therapies

Publications (2)

Publication Number Publication Date
KR20160044529A KR20160044529A (ko) 2016-04-25
KR102389240B1 true KR102389240B1 (ko) 2022-04-20

Family

ID=52484194

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167006785A Active KR102389240B1 (ko) 2013-08-22 2014-08-22 면역-종양 살상 요법

Country Status (27)

Country Link
US (2) US11478518B2 (enExample)
EP (3) EP3778897B1 (enExample)
JP (3) JP6912199B2 (enExample)
KR (1) KR102389240B1 (enExample)
CN (1) CN105658795B (enExample)
AU (1) AU2014308648B2 (enExample)
CA (3) CA3213715A1 (enExample)
DK (2) DK3036329T3 (enExample)
EA (1) EA037582B1 (enExample)
ES (2) ES2971528T3 (enExample)
FI (1) FI3778897T3 (enExample)
HR (1) HRP20240078T1 (enExample)
HU (1) HUE066593T2 (enExample)
IL (1) IL243996A0 (enExample)
LT (1) LT3778897T (enExample)
MD (2) MD4624C1 (enExample)
MX (1) MX2016002257A (enExample)
NZ (1) NZ716825A (enExample)
PE (1) PE20160673A1 (enExample)
PH (1) PH12016500329A1 (enExample)
PL (1) PL3778897T3 (enExample)
PT (1) PT3778897T (enExample)
RS (1) RS65104B1 (enExample)
SG (1) SG11201600960PA (enExample)
SI (1) SI3778897T1 (enExample)
SM (1) SMT202400047T1 (enExample)
WO (1) WO2015027163A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778897B1 (en) * 2013-08-22 2023-12-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Immuno-oncolytic therapies
JP2018510143A (ja) 2015-02-25 2018-04-12 メモリアル スローン ケタリング キャンサー センター 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US10370647B2 (en) * 2015-07-22 2019-08-06 National University Corporation Tottori University Host regulatory factor that enhances replication and/or propagation of vaccinia virus
CA2996120C (en) * 2015-09-08 2024-02-20 Sillajen, Inc. Modified oncolytic vaccinia viruses expressing a cytokine and a carboxylesterase and methods of use thereof
JP2018532810A (ja) 2015-11-07 2018-11-08 マルチビア インコーポレイテッド がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
BR112018016948A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
BR112018016949A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer
US12150969B2 (en) * 2016-03-25 2024-11-26 University of Pittsburgh—of the Commonwealth System of Higher Education Synthetically enveloped virus
EP3254692A1 (en) * 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
AU2017298385A1 (en) 2016-07-19 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting STAT3
KR20190059297A (ko) * 2016-09-21 2019-05-30 스티븐 에이치. 쏜 고-이동성 군 박스 1 돌연변이체
GB201616365D0 (en) 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
AU2018215558B2 (en) * 2017-02-03 2023-05-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
JP7206212B2 (ja) * 2017-03-06 2023-01-17 タラリス・セラピューティクス・インコーポレイテッド 治療用細胞組成物の効力を決定するための方法及び組成物
WO2018195552A1 (en) * 2017-04-21 2018-10-25 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN111556757A (zh) * 2017-10-31 2020-08-18 西方溶瘤细胞有限公司 用于全身递送的平台溶瘤载体
US11633441B2 (en) 2017-12-01 2023-04-25 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
JP7312412B2 (ja) 2018-01-05 2023-07-21 オタワ ホスピタル リサーチ インスティチュート 改変オルトポックスウイルスベクター
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
KR20210032495A (ko) * 2018-07-20 2021-03-24 안선 바이오파르마, 아이엔씨. 암 세포, 면역 세포 및 종양 미세환경에 시알리다제의 전달
WO2020056424A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
KR20210132003A (ko) * 2018-12-21 2021-11-03 오타와 하스피털 리서치 인스티튜트 변형된 오르토폭스 바이러스 벡터
KR20210113632A (ko) * 2019-01-07 2021-09-16 칼리버 임뮤노쎄라퓨틱스, 인크. 암을 치료하는 방법
TW202038994A (zh) * 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
EP3923967A1 (en) 2019-02-14 2021-12-22 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP7326663B2 (ja) * 2019-08-26 2023-08-16 バイオノックス インコーポレイテッド がんの処置のための活性成分としてワクシニアウイルス及びヒドロキシ尿素を含む医薬組成物
WO2021076982A1 (en) * 2019-10-16 2021-04-22 KaliVir Immunotherapeutics LLC Modified extracellular enveloped virus
EP4061417A4 (en) * 2019-11-20 2023-10-11 University of Pittsburgh - of the Commonwealth System of Higher Education VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
IL293627A (en) * 2019-12-12 2022-08-01 Ignite Immunotherapy Inc Variant oncolytic vaccinia virus and methods of use thereof
US20230201283A1 (en) * 2020-01-09 2023-06-29 Pfizer Inc. Recombinant vaccinia virus
CN115243714A (zh) * 2020-03-06 2022-10-25 匹兹堡大学联邦系统高等教育 用于治疗癌症的表达irf调节剂的溶瘤病毒
KR20230110545A (ko) 2020-11-19 2023-07-24 칼리버 임뮤노쎄라퓨틱스, 인크. 종양 미세환경 재형성에 의한 종양용해 면역요법
MX2023012608A (es) * 2021-04-30 2023-11-03 Kalivir Immunotherapeutics Inc Virus oncoliticos para la expresion modificada del mhc.
CA3224374A1 (en) * 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9305855A (es) 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
WO2000073479A1 (en) 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
CN101912421A (zh) * 2002-08-12 2010-12-15 杰能斯有限公司 涉及痘病毒和癌的方法及组合物
JPWO2007023725A1 (ja) * 2005-08-25 2009-02-26 公立大学法人横浜市立大学 遺伝子ワクチン
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US9180149B2 (en) * 2005-09-07 2015-11-10 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2009124044A2 (en) * 2008-03-31 2009-10-08 University Of Florida Research Foundation, Inc. Tumor growth inhibition via conditioning of tumor microenvironment
AU2010291901C1 (en) 2009-09-14 2016-03-03 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus combination cancer therapy
US20130202639A1 (en) 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
US11149254B2 (en) * 2011-04-15 2021-10-19 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
WO2014047350A1 (en) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
EP3778897B1 (en) 2013-08-22 2023-12-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Immuno-oncolytic therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH. 2001, vol. 61, no. 24, pages 8751-8757.*
Cytokine. 2011, vol. 56, no. 1, page 84.
VIROLOGY. 1977, vol. 78, no. 1, pages 315-322.

Also Published As

Publication number Publication date
PT3778897T (pt) 2024-02-01
KR20160044529A (ko) 2016-04-25
EP3778897A1 (en) 2021-02-17
SG11201600960PA (en) 2016-03-30
CA2921041A1 (en) 2015-02-26
HRP20240078T1 (hr) 2024-03-29
HK1223402A1 (zh) 2017-07-28
CA3213715A1 (en) 2015-02-26
JP2022062171A (ja) 2022-04-19
DK3036329T3 (da) 2021-01-11
AU2014308648B2 (en) 2020-11-12
HUE066593T2 (hu) 2024-08-28
FI3778897T3 (fi) 2024-01-25
MD4748B1 (ro) 2021-02-28
EP4324918A3 (en) 2024-04-24
EP3036329A4 (en) 2017-08-02
NZ716825A (en) 2022-02-25
WO2015027163A1 (en) 2015-02-26
JP7021154B2 (ja) 2022-02-16
DK3778897T3 (da) 2024-01-29
EP3036329B1 (en) 2020-10-07
SI3778897T1 (sl) 2024-03-29
US20230008089A1 (en) 2023-01-12
PL3778897T3 (pl) 2024-04-02
US12514888B2 (en) 2026-01-06
EP3036329A1 (en) 2016-06-29
US11478518B2 (en) 2022-10-25
MD4624B1 (ro) 2019-03-31
EA037582B1 (ru) 2021-04-16
PH12016500329A1 (en) 2016-05-02
MD4624C1 (ro) 2019-10-31
MX2016002257A (es) 2016-11-08
MD20160027A2 (ro) 2016-08-31
MD20180086A2 (ro) 2019-03-31
CN105658795A (zh) 2016-06-08
CA2921041C (en) 2023-10-31
ES2971528T3 (es) 2024-06-05
EA201690444A1 (ru) 2016-08-31
US20160235793A1 (en) 2016-08-18
MD4748C1 (ro) 2021-09-30
CN105658795B (zh) 2020-07-03
PE20160673A1 (es) 2016-07-21
IL243996A0 (en) 2016-04-21
EP3778897B1 (en) 2023-12-20
JP6912199B2 (ja) 2021-08-04
AU2014308648A1 (en) 2016-03-03
JP2019205451A (ja) 2019-12-05
CA3213683A1 (en) 2015-02-26
ES2847305T3 (es) 2021-08-02
JP2016527920A (ja) 2016-09-15
EP4324918A2 (en) 2024-02-21
LT3778897T (lt) 2024-02-12
WO2015027163A9 (en) 2016-04-14
JP7333431B2 (ja) 2023-08-24
RS65104B1 (sr) 2024-02-29
SMT202400047T1 (it) 2024-03-13

Similar Documents

Publication Publication Date Title
US12514888B2 (en) Immuno-oncolytic therapies
AU2014308648A2 (en) Immuno-oncolytic therapies
US20250332208A1 (en) Oncolytic virus therapy
JP7025339B2 (ja) 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
CN116162654A (zh) 用于癌症免疫疗法的重组痘病毒
KR20200026894A (ko) 개인 맞춤형 백신
US11884939B2 (en) Vaccinia virus mutants useful for cancer immunotherapy
CN114786715A (zh) 痘苗病毒和使用痘苗病毒的方法
HK40104741A (en) Immuno-oncolytic therapies
HK40045119A (en) Immuno-oncolytic therapies
HK40045119B (en) Immuno-oncolytic therapies
HK1223402B (zh) 免疫溶瘤療法
US20220211814A1 (en) Il-36 cytokine expressing oncolytic viruses for treating cancer
HK40088792A (zh) 用於癌症免疫疗法的重组痘病毒

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160315

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190822

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200713

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200713

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210128

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200914

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190822

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210408

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20220123

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210907

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210302

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210128

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200914

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190822

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220418

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220418

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250317

Start annual number: 4

End annual number: 4